Trimethylamine N-oxide (TMAO)

Trimethylamine N-oxide (TMAO) is a gut-microbiota-derived metabolite that serves as a significant physiological osmolyte and has emerged as a key therapeutic target and biomarker in cardiovascular and metabolic medicine (Austin J Cardiovasc Dis Atherosclerosis 2023). It is produced via a meta-organismal pathway where dietary nutrients like choline, L-carnitine, and betaine are converted into trimethylamine (TMA) by gut bacterial enzymes (e.g., CutC/D), followed by oxidation in the liver by flavin-containing monooxygenases, predominantly FMO3 (Annual Reviews 2017). While TMAO plays a role in osmoregulation and protein folding, its pathological elevation is strongly linked to the progression of atherosclerosis, heart failure, and chronic kidney disease by promoting vascular inflammation, oxidative stress, and platelet hyperreactivity (MDPI Metabolites 2023). Mechanistically, TMAO exerts its detrimental effects by activating the NLRP3 inflammasome and inducing ER stress through direct interactions with receptors such as protein kinase R-like endoplasmic reticulum kinase (PERK) (Frontiers 2024). Therapeutic strategies to modulate TMAO levels include dietary interventions, the use of non-lethal small-molecule inhibitors of microbial TMA-lyases (such as DMB and IMC), and pharmacological agents that enhance renal clearance or inhibit hepatic oxidation (PMC 9205510). Consequently, TMAO represents a unique target at the interface of the gut microbiome and systemic host metabolism, offering a novel approach to managing chronic inflammatory and cardiovascular disorders.

Other names

Trimethylamine oxideTMA-oxideN,N-dimethylmethanamine N-oxideTrimethylamine N-oxide dihydrate

Reduction of systemic levels through inhibition of microbial choline TMA lyases (CutC/D), inhibition of hepatic flavin-containing monooxygenase 3 (FMO3), acceleration of renal excretion, or direct chemical reduction back to trimethylamine.